Singapore, Nov 20, 2009: Farnham-UK based medical technology company Biocompatibles has acquisition the inventory and intellectual property assets of Astron Clinica for around $400,000.
Astron’s principal products, MoleMate and MoleView broaden the product portfolio of Biocompatibles’ Oncology Products Division and are non-invasive melanoma visualization, diagnostic and data storage systems that are sold to General Practitioners, Dermatologists and cancer screening clinics.
The technology is already in use mostly in Australia and in the UK and will be progressively launched into more territories during the course of 2010, a company release said.
The technology has been evaluated in three clinical trials which have recruited more than 1500 patients assessed with MoleMate.
Crispin Simon, Chief Executive Officer said, “Most people are aware of the benefits of timely cancer screening. Melanoma is relatively easy to screen yet typically fatal if detected late. This technology delivers accurate results at an affordable cost in a location, such as a GP’s surgery, that is convenient to patients.”
| 
Comment on this article
